These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 32519928)

  • 21. Effects of Patisiran, an RNA Interference Therapeutic, on Cardiac Parameters in Patients With Hereditary Transthyretin-Mediated Amyloidosis.
    Solomon SD; Adams D; Kristen A; Grogan M; González-Duarte A; Maurer MS; Merlini G; Damy T; Slama MS; Brannagan TH; Dispenzieri A; Berk JL; Shah AM; Garg P; Vaishnaw A; Karsten V; Chen J; Gollob J; Vest J; Suhr O
    Circulation; 2019 Jan; 139(4):431-443. PubMed ID: 30586695
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advances in the treatment of hereditary transthyretin amyloidosis: A review.
    Gertz MA; Mauermann ML; Grogan M; Coelho T
    Brain Behav; 2019 Sep; 9(9):e01371. PubMed ID: 31368669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.
    Suhr OB; Coelho T; Buades J; Pouget J; Conceicao I; Berk J; Schmidt H; Waddington-Cruz M; Campistol JM; Bettencourt BR; Vaishnaw A; Gollob J; Adams D
    Orphanet J Rare Dis; 2015 Sep; 10():109. PubMed ID: 26338094
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel RNA-targeted therapies for hereditary ATTR amyloidosis and their impact on the autonomic nervous system.
    Conceição I
    Clin Auton Res; 2019 Sep; 29(Suppl 1):11-17. PubMed ID: 31399774
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
    Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
    J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of baseline polyneuropathy severity on patisiran treatment outcomes in the APOLLO trial.
    Quan D; Obici L; Berk JL; Ando Y; Aldinc E; White MT; Adams D
    Amyloid; 2023 Mar; 30(1):49-58. PubMed ID: 36120830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathy.
    Waddington Cruz M; Amass L; Keohane D; Schwartz J; Li H; Gundapaneni B
    Amyloid; 2016 Sep; 23(3):178-183. PubMed ID: 27494299
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial.
    Adams D; Tournev IL; Taylor MS; Coelho T; Planté-Bordeneuve V; Berk JL; González-Duarte A; Gillmore JD; Low SC; Sekijima Y; Obici L; Chen C; Badri P; Arum SM; Vest J; Polydefkis M;
    Amyloid; 2023 Mar; 30(1):1-9. PubMed ID: 35875890
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy.
    Merkel M; Danese D; Chen C; Wang J; Wu A; Yang H; Lin H
    Expert Opin Pharmacother; 2023; 24(10):1205-1214. PubMed ID: 37219406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
    Paton DM
    Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patisiran for the treatment of hereditary transthyretin-mediated amyloidosis.
    Yang J
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):95-99. PubMed ID: 30644768
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An evaluation of patisiran: a viable treatment option for transthyretin-related hereditary amyloidosis.
    Milani P; Mussinelli R; Perlini S; Palladini G; Obici L
    Expert Opin Pharmacother; 2019 Dec; 20(18):2223-2228. PubMed ID: 31566422
    [No Abstract]   [Full Text] [Related]  

  • 33. [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
    Sekijima Y
    Brain Nerve; 2014 Jul; 66(7):773-81. PubMed ID: 24998822
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label study.
    Ando Y; Sekijima Y; Obayashi K; Yamashita T; Ueda M; Misumi Y; Morita H; Machii K; Ohta M; Takata A; Ikeda S
    J Neurol Sci; 2016 Mar; 362():266-71. PubMed ID: 26944161
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Response to the letter to the editor on "an indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
    Lin H; Agarwal S; Betts M; Fahrbach K; Chitnis M; Polydefkis M
    Expert Opin Pharmacother; 2019 Aug; 20(12):1529-1530. PubMed ID: 31124741
    [No Abstract]   [Full Text] [Related]  

  • 36. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial.
    Keohane D; Schwartz J; Gundapaneni B; Stewart M; Amass L
    Amyloid; 2017 Mar; 24(1):30-36. PubMed ID: 28393570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recent progress in the understanding and treatment of transthyretin amyloidosis.
    Sekijima Y
    J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Letter to the editor concerning the article: "An indirect treatment comparison of the efficacy of patisiran and tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy".
    Salvo EM; Samjoo IA; Tran D; Cameron C
    Expert Opin Pharmacother; 2019 Aug; 20(12):1527-1528. PubMed ID: 31124724
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment with patisiran of a patient with hereditary transthyretin-mediated amyloidosis with stage 3 polyneuropathy.
    Müschen LH; Körner G; Gingele S; Hänselmann A; Bavendiek U; Skripuletz T
    Muscle Nerve; 2021 Sep; 64(3):E11-E13. PubMed ID: 34075597
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy.
    Coelho T; Maia LF; da Silva AM; Cruz MW; Planté-Bordeneuve V; Suhr OB; Conceiçao I; Schmidt HH; Trigo P; Kelly JW; Labaudinière R; Chan J; Packman J; Grogan DR
    J Neurol; 2013 Nov; 260(11):2802-14. PubMed ID: 23974642
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.